beta-alanine has been researched along with Brain Ischemia in 23 studies
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 9.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation." | 7.80 | Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. ( Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A, 2014) |
| "A 70-year-old man with multiple ischemic strokes was diagnosed with cardiac embolism and treated with dabigatran." | 7.80 | Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran. ( Aburakawa, Y; Kimura, T; Kuroda, K; Suzuki, Y; Yahara, O; Yoshida, K, 2014) |
| " Indication for dabigatran etexilate was ischemic stroke in 101 patients and acute cerebral hemorrhage (CH) due to warfarin in 5 (4." | 7.80 | Dabigatran in secondary stroke prevention: clinical experience with 106 patients. ( Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R, 2014) |
| "In an 89-year-old female with atrial fibrillation dabigatran had been started 11 days before admission, following a transitory ischemic attack." | 7.79 | Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. ( Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C, 2013) |
| "Randomized trials suggest superior and safe stroke prevention in patients with atrial fibrillation after anticoagulation with dabigatran (D) at a 150 mg BID as described in the RE-LY prospective randomized open-label trial when compared to warfarin." | 7.78 | Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. ( Fong, A; Hanley, D; Lynch, D; Sani, Y; Schevchuck, A; Serebruany, V; Svetlov, S; Thevathasan, L, 2012) |
| "NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin." | 6.49 | [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013) |
| "Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 5.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation." | 3.80 | Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. ( Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A, 2014) |
| "A 70-year-old man with multiple ischemic strokes was diagnosed with cardiac embolism and treated with dabigatran." | 3.80 | Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran. ( Aburakawa, Y; Kimura, T; Kuroda, K; Suzuki, Y; Yahara, O; Yoshida, K, 2014) |
| " Indication for dabigatran etexilate was ischemic stroke in 101 patients and acute cerebral hemorrhage (CH) due to warfarin in 5 (4." | 3.80 | Dabigatran in secondary stroke prevention: clinical experience with 106 patients. ( Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R, 2014) |
| "In an 89-year-old female with atrial fibrillation dabigatran had been started 11 days before admission, following a transitory ischemic attack." | 3.79 | Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. ( Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C, 2013) |
| "Randomized trials suggest superior and safe stroke prevention in patients with atrial fibrillation after anticoagulation with dabigatran (D) at a 150 mg BID as described in the RE-LY prospective randomized open-label trial when compared to warfarin." | 3.78 | Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. ( Fong, A; Hanley, D; Lynch, D; Sani, Y; Schevchuck, A; Serebruany, V; Svetlov, S; Thevathasan, L, 2012) |
| "We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age." | 3.78 | [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012) |
| " The dosage of warfarin requires regular adjustment dependent on the INR, to keep within a narrow therapeutic range of 2." | 2.50 | Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? ( Foley, J; Kirchhof, P; Lip, GY, 2014) |
| "NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin." | 2.49 | [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013) |
| "Stroke is a common disease, which is associated with high morbidity and high mortality." | 2.49 | [Anticoagulant therapy in stroke patients]. ( Grove, EL; Husted, SE; Kraglund, KL; Modrau, B, 2013) |
| "Cardioembolic cerebral ischemia can be prevented." | 2.48 | [Prevention of cardioembolic stroke]. ( Gil Núñez, A, 2012) |
| "Brain ischemic stroke is among the leading causes of death and long-term disability." | 1.72 | Multi-target action of β-alanine protects cerebellar tissue from ischemic damage. ( Kopach, O; Rusakov, DA; Sylantyev, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 20 (86.96) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Kopach, O | 1 |
| Rusakov, DA | 1 |
| Sylantyev, S | 1 |
| Folyovich, A | 1 |
| Varga, V | 1 |
| Béres-Molnár, KA | 1 |
| Vadasdi, K | 1 |
| Bereczki, D | 1 |
| Szapary, L | 1 |
| Fehér, G | 1 |
| Bosnyák, E | 1 |
| Deli, G | 1 |
| Csécsei, P | 1 |
| Müller, P | 1 |
| Topakian, R | 1 |
| Sonnberger, M | 1 |
| Nußbaumer, K | 1 |
| Windpessl, M | 1 |
| Eder, V | 1 |
| Nesser, HJ | 1 |
| Trenkler, J | 1 |
| Haring, HP | 1 |
| Kono, S | 1 |
| Deguchi, K | 1 |
| Omote, Y | 1 |
| Yunoki, T | 1 |
| Yamashita, T | 1 |
| Kurata, T | 1 |
| Ikeda, Y | 1 |
| Abe, K | 1 |
| Finsterer, J | 2 |
| Stöllberger, C | 2 |
| Paul, G | 1 |
| Bastovansky, A | 1 |
| Kate, M | 1 |
| Szkotak, A | 1 |
| Witt, A | 1 |
| Shuaib, A | 1 |
| Butcher, K | 1 |
| Yoshida, K | 1 |
| Kimura, T | 1 |
| Aburakawa, Y | 1 |
| Suzuki, Y | 1 |
| Kuroda, K | 1 |
| Yahara, O | 1 |
| Foley, J | 1 |
| Kirchhof, P | 1 |
| Lip, GY | 1 |
| DeFelipe-Mimbrera, A | 1 |
| Alonso Cánovas, A | 1 |
| Guillán, M | 1 |
| Matute, C | 1 |
| Sainz de la Maza, S | 1 |
| Cruz, A | 1 |
| Vera, R | 1 |
| Masjuan, J | 1 |
| Gil Núñez, A | 2 |
| Takeuchi, S | 1 |
| Wada, K | 1 |
| Nagatani, K | 1 |
| Otani, N | 1 |
| Osada, H | 1 |
| Nawashiro, H | 1 |
| Serebruany, V | 1 |
| Sani, Y | 1 |
| Lynch, D | 1 |
| Schevchuck, A | 1 |
| Svetlov, S | 1 |
| Fong, A | 1 |
| Thevathasan, L | 1 |
| Hanley, D | 1 |
| Diener, HC | 1 |
| Eikelboom, J | 2 |
| Granger, CB | 1 |
| Hacke, W | 1 |
| Healey, JS | 1 |
| Douketis, J | 1 |
| Wallentin, L | 1 |
| Oldgren, J | 1 |
| Yang, S | 1 |
| Themeles, E | 1 |
| Heidbuchel, H | 1 |
| Heidbuchle, H | 1 |
| Avezum, A | 1 |
| Reilly, P | 1 |
| Connolly, SJ | 1 |
| Yusuf, S | 1 |
| Ezekowitz, M | 1 |
| Rakusan, S | 1 |
| Wimpissinger, FT | 1 |
| Shevelev, VI | 1 |
| Kanorsky, SG | 1 |
| Kraglund, KL | 1 |
| Husted, SE | 1 |
| Modrau, B | 1 |
| Grove, EL | 1 |
| de Gea-García, JH | 1 |
| Alvarez, M | 1 |
| Ruiz-Villa, G | 1 |
| Jiménez-Parra, JD | 1 |
| Re, G | 1 |
| Toni, D | 1 |
| Allen, NJ | 1 |
| Rossi, DJ | 1 |
| Attwell, D | 1 |
| Saransaari, P | 1 |
| Oja, SS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants[NCT02185027] | 1,166 participants (Actual) | Observational | 2013-06-30 | Completed | |||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
4 reviews available for beta-alanine and Brain Ischemia
| Article | Year |
|---|---|
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2013 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine | 2014 |
[Prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Doubl | 2012 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral He | 2013 |
1 trial available for beta-alanine and Brain Ischemia
18 other studies available for beta-alanine and Brain Ischemia
| Article | Year |
|---|---|
Multi-target action of β-alanine protects cerebellar tissue from ischemic damage.
Topics: beta-Alanine; Brain; Brain Injuries; Brain Ischemia; Humans; Neuroprotective Agents; Stroke | 2022 |
Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
Endovascular thrombectomy for acute ischemic stroke patients anticoagulated with dabigatran.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia | 2013 |
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Disease Models, An | 2014 |
Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Isc | 2013 |
Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coa | 2014 |
Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Heparin, Low-Molecula | 2014 |
Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Hemorrhag | 2014 |
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2010 |
Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Fibrinolytic Agents; Human | 2012 |
Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.
Topics: Aged; Automation; Benzimidazoles; beta-Alanine; Biomarkers; Brain Ischemia; Calibration; Dabigatran; | 2012 |
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrha | 2012 |
Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antithrombins; Atrial Fibrillati | 2012 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2012 |
[Wünderlich syndrome in patient anticoagulated with dabigatran].
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia | 2013 |
Thrombolysis in ischemic stroke patients on treatment with Dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Humans; Stroke; Thrombolyti | 2013 |
Sequential release of GABA by exocytosis and reversed uptake leads to neuronal swelling in simulated ischemia of hippocampal slices.
Topics: Action Potentials; Animals; beta-Alanine; Brain Ischemia; Calcium; Carrier Proteins; Cell Size; Exci | 2004 |
Characteristics of ischemia-induced taurine release in the developing mouse hippocampus.
Topics: Animals; beta-Alanine; Brain Ischemia; Carrier Proteins; Female; Hippocampus; In Vitro Techniques; K | 1999 |